Welcome to our dedicated page for Valneva SE SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE filings document a foreign private issuer focused on prophylactic vaccines for infectious diseases. Its Form 6-K reports and Form 20-F disclosures cover consolidated financial results, product sales, research collaboration revenue, and business updates for marketed vaccines and clinical-stage programs, including Lyme disease, Shigella and chikungunya vaccine activities.
The filing record also includes material-event disclosures incorporated by reference into Form F-3 registration statements. These documents address material agreements, licensing and collaboration arrangements, capital-structure actions, shareholder voting and governance matters, risk factors, and clinical or regulatory updates for Valneva's vaccine candidates and commercial portfolio.
Valneva SE (VALN) filed a routine Form 6-K with the U.S. SEC on 25 June 2025. The submission simply furnishes a company press release dated the same day as Exhibit 99.1 and explicitly incorporates that release into Valneva’s effective shelf Registration Statement on Form F-3 (File No. 333-286071). No financial statements, earnings figures, or transactional details accompany the filing. The document, signed by CEO and President Thomas Lingelbach, serves an administrative purpose—ensuring U.S. investors have access to the referenced press release within Valneva’s formal disclosure record.